A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure
In this randomized, double-blind, placebo-controlled, multicentre, parallel, 8-week study, the efficacy of a daily dose of 1200 mg of protein hydrolysate from Coldwater Shrimp (Pandalus borealis) on ambulatory and office blood pressure was investigated in 144 free-living adults with mild to moderate...
Published in: | International Journal of Hypertension |
---|---|
Main Authors: | , , , |
Format: | Report |
Language: | English |
Published: |
International Journal of Hypertension
2019
|
Subjects: | |
Online Access: | https://doi.org/10.1155/2019/2345042 |
id |
fthindawi:oai:hindawi.com:10.1155/2019/2345042 |
---|---|
record_format |
openpolar |
spelling |
fthindawi:oai:hindawi.com:10.1155/2019/2345042 2023-05-15T17:54:32+02:00 A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans 2019 https://doi.org/10.1155/2019/2345042 en eng International Journal of Hypertension https://doi.org/10.1155/2019/2345042 Copyright © 2019 Kathy Musa-Veloso et al. Clinical Study 2019 fthindawi https://doi.org/10.1155/2019/2345042 2019-08-08T14:47:29Z In this randomized, double-blind, placebo-controlled, multicentre, parallel, 8-week study, the efficacy of a daily dose of 1200 mg of protein hydrolysate from Coldwater Shrimp (Pandalus borealis) on ambulatory and office blood pressure was investigated in 144 free-living adults with mild to moderate hypertension. The primary outcomes of the study were daytime ambulatory systolic blood pressure and office blood pressure. During the 8-week intervention period and in the intention-to-treat analysis (n=144), there were significant reductions in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group in daytime ambulatory systolic blood pressure at 4 weeks (p=0.014) and at 8 weeks (p=0.002), and in office systolic blood pressure at 2 weeks (p=0.031) and 4 weeks (p=0.010), with a trend toward significance at 8 weeks (p=0.087). By 8 weeks, significant and favourable improvements in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group were also observed for several secondary outcomes, including 24-hour ambulatory systolic and diastolic blood pressure, daytime ambulatory diastolic blood pressure, and daytime and 24-hour ambulatory mean arterial pressure. Also by Week 8, there was a statistically significant difference between groups in the distribution of subjects across National Institutes of Health-defined blood pressure categories (i.e., Normotensive, Prehypertensive, Stage 1 hypertension, and Stage 2 hypertension), with a more favourable distribution in the shrimp-derived protein hydrolysate group than in the placebo group (p=0.006). Based on exploratory analyses conducted only in participants in the shrimp-derived protein hydrolysate group, angiotensin II levels were significantly reduced relative to baseline. This study is registered at ClinicalTrials.gov NCT01974570. Report Pandalus borealis Hindawi Publishing Corporation International Journal of Hypertension 2019 1 13 |
institution |
Open Polar |
collection |
Hindawi Publishing Corporation |
op_collection_id |
fthindawi |
language |
English |
description |
In this randomized, double-blind, placebo-controlled, multicentre, parallel, 8-week study, the efficacy of a daily dose of 1200 mg of protein hydrolysate from Coldwater Shrimp (Pandalus borealis) on ambulatory and office blood pressure was investigated in 144 free-living adults with mild to moderate hypertension. The primary outcomes of the study were daytime ambulatory systolic blood pressure and office blood pressure. During the 8-week intervention period and in the intention-to-treat analysis (n=144), there were significant reductions in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group in daytime ambulatory systolic blood pressure at 4 weeks (p=0.014) and at 8 weeks (p=0.002), and in office systolic blood pressure at 2 weeks (p=0.031) and 4 weeks (p=0.010), with a trend toward significance at 8 weeks (p=0.087). By 8 weeks, significant and favourable improvements in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group were also observed for several secondary outcomes, including 24-hour ambulatory systolic and diastolic blood pressure, daytime ambulatory diastolic blood pressure, and daytime and 24-hour ambulatory mean arterial pressure. Also by Week 8, there was a statistically significant difference between groups in the distribution of subjects across National Institutes of Health-defined blood pressure categories (i.e., Normotensive, Prehypertensive, Stage 1 hypertension, and Stage 2 hypertension), with a more favourable distribution in the shrimp-derived protein hydrolysate group than in the placebo group (p=0.006). Based on exploratory analyses conducted only in participants in the shrimp-derived protein hydrolysate group, angiotensin II levels were significantly reduced relative to baseline. This study is registered at ClinicalTrials.gov NCT01974570. |
format |
Report |
author |
Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans |
spellingShingle |
Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
author_facet |
Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans |
author_sort |
Kathy Musa-Veloso |
title |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_short |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_full |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_fullStr |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_full_unstemmed |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_sort |
randomized, double-blind, placebo-controlled, multicentre trial of the effects of a shrimp protein hydrolysate on blood pressure |
publisher |
International Journal of Hypertension |
publishDate |
2019 |
url |
https://doi.org/10.1155/2019/2345042 |
genre |
Pandalus borealis |
genre_facet |
Pandalus borealis |
op_relation |
https://doi.org/10.1155/2019/2345042 |
op_rights |
Copyright © 2019 Kathy Musa-Veloso et al. |
op_doi |
https://doi.org/10.1155/2019/2345042 |
container_title |
International Journal of Hypertension |
container_volume |
2019 |
container_start_page |
1 |
op_container_end_page |
13 |
_version_ |
1766162321993891840 |